HCP Live

Dr. Madduri on the Results of the CARTITUDE-1 Trial in Multiple Myeloma

Dec 9, 2019

Deepu Madduri, MD

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses the results of the phase Ib/II CARTITUDE-1 trial of the BCMA-directed CAR T-cell therapy JNJ-4528 in patients with heavily pretreated relapsed/refractory multiple myeloma.

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses the results of the phase Ib/II CARTITUDE-1 trial of the BCMA-directed CAR T-cell therapy JNJ-4528 in patients with heavily pretreated relapsed/refractory multiple myeloma.

<<< View more from the 2019 ASH Annual Meeting

Related Videos

$Binod Dhakal, MD, on Assessing Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma$

Brian Van Tine, MD, PhD, on Further Research With Cell Therapy in Synovial Sarcoma

Brian Van Tine, MD, PhD, on Continued Durability of Afami-Cel in Synovial Sarcoma

Thomas McCauley, PhD, on Treating Solid Tumors With Epigenomic Controllers

Rebecca Cottman, PhD, on Creating Regulated Gene Circuits to Enhance Cell Therapy Cytotoxicity

John Leonard, PhD, on an AAV Approach to Exon 51 Skipping in DMD

Joseph Fraietta, PhD, on Investigating Molecular Pathways of CAR T-Cell Resistance

Related Content

New Findings May Help Bolster CRISPR/Cas9 Accuracy

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

Gene Editing Trial Underway in Pediatric Methylmalonic Acidemia

New Findings May Help Bolster CRISPR/Cas9 Accuracy

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

Gene Editing Trial Underway in Pediatric Methylmalonic Acidemia

New Findings May Help Bolster CRISPR/Cas9 Accuracy

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

Gene Editing Trial Underway in Pediatric Methylmalonic Acidemia

Related Content

David Taylor, PhD

New Findings May Help Bolster CRISPR/Cas9 Accuracy

David Taylor, PhD, an assistant professor in the department of molecular biosciences at UT Austin, discussed the Cas9 research conducted between 2 labs at UT Austin.

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

The recommendation comes after positive data was released from the recent phase 2 KarMMa trial.

Mariana Nacht, PhD

Gene Editing Trial Underway in Pediatric Methylmalonic Acidemia

The therapy utilizes LogicBio’s GeneRide technology to insert a corrective copy of the target gene via synthetic AAV vectors.

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.